Ivarmacitinib

ApprovedSmall molecule

FFudan University

Ivarmacitinib is one of 77 small molecule programs targeting Polymyalgia Rheumatica. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polymyalgia RheumaticaActive, not recruiting

Palmoplantar PustulosisActive, not recruiting

Behcet's SyndromeWithdrawn

Rheumatoid ArthritisActive, not recruiting

Polymyalgia RheumaticaPreclinical

Active, not recruiting

Palmoplantar PustulosisPreclinical

Active, not recruiting

Behcet's SyndromePhase 2

Withdrawn

Rheumatoid ArthritisApproved

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Ivarmacitinib

FFudan University

Approved

1 2

Orencia

Bristol-Myers Squibb

Preclinical

47 3

Actemra

Rituxan

61 5

Cimzia

UCB

Preclinical

30 6

Simponi

Johnson & Johnson

Preclinical

19 7

Actos

Takeda

Preclinical

2 8

Celexa

AbbVie

Preclinical

1 9

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 10

Kineret

SSwedish Orphan Biovitrum

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Palmoplantar Pustulosis

NCT07270003

Q4 2027

Phase 2Not yet recruiting

Immunotherapy

NCT06731153

Phase 1/2Not yet recruiting

Efficacy and Safety

NCT07381114

Q4 2028

N/ANot yet recruiting

Polymyalgia Rheumatica

NCT07266168

Phase 2Not yet recruiting

Advanced Solid Tumors

NCT07313202

Q1 2029

Post-ApprovalNot yet recruiting

Rheumatoid Arthritis

NCT07452445

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT07381114·32 enrolled

Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis

Not yet recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT07451665·180 enrolled

Palmoplantar Pustulosis1 trial

A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis

Recruiting·XXijing Hospital·N/A·NCT07270003·60 enrolled

Immunotherapy1 trial

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Not yet recruiting·FFudan University·Phase 2·NCT06731153·40 enrolled

Rheumatoid Arthritis1 trial

Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis

Not yet recruiting·TTongji Hospital·Phase 4·NCT07452445·100 enrolled

Polymyalgia Rheumatica1 trial

Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia Rheumatica

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07266168·80 enrolled

2 more indications

Advanced Solid Tumors1 trial

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07313202·72 enrolled

Behcet's syndrome1 trial

Efficacy and Safety of the Novel, Highly Selective JAK Inhibitor Ivarmacitinib in the Treatment of Behçet's Disease: A Multicenter Prospective Study

Withdrawn·LLiu Tian·Phase 2·NCT07634848

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Ivarmacitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ivarmacitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ivarmacitinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFudan University

Ivarmacitinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2028

Q1 2029

Trials by Indication[1]

Efficacy and Safety2 trials

Palmoplantar Pustulosis1 trial

Immunotherapy1 trial

Rheumatoid Arthritis1 trial

Polymyalgia Rheumatica1 trial

Advanced Solid Tumors1 trial

Behcet's syndrome1 trial

References

Drug Info

Quick Facts

Related News